LOS ANGELES, May 19 /PRNewswire/ — ImaginAb, Inc. and
the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group
of Companies) have concluded two research collaboration agreements
around a clinical therapeutic antibody asset currently under
development by GSK in the field of oncology.
“ImaginAb is pleased to have formalized this collaboration with
the GSK CIC,” said Dr. Christian
Behrenbruch, CEO of ImaginAb. “Not only does GSK have an
excellent biologics pipeline, but the company’s large-scale
commitment to diagnostic imaging is extremely impressive and this
particular collaboration is a natural fit with ImaginAb’s
technology platform.”
“Our collaboration with ImaginAb for antibody fragment imaging
is part of our further exploration of the role of biologics in
diagnostic imaging with Positron Emission Tomography (PET), an
increasingly important clinical modality and a tool that is of
significant interest to pharma in the discovery and development of
new therapeutics,” commented Dr. Paul
Matthews, VP for Translational Research and Head of the GSK
CIC. “As we expand and develop our pipeline, technologies such as
ImaginAb’s recombinant antibody fragment engineering technology may
help us to look at targeted molecular therapeutics in new
ways.”
About GSK Clinical Imaging Centre
GlaxoSmithKline (GSK), Imperial College London (ICL) and the
Medical Research Centre (MRC) have established a unique research
collaboration in medical imaging, creating a Clinical Imaging
Centre (CIC) based at Hammersmith Hospital in West London. The GSK CIC uses and
advances the latest technologies in magnetic resonance imaging
(MRI) and positron emission tomography (PET). R
‘/>”/>